Skip to main content

Tables 3 Proliferative capacity and lifespan of TCCs on antioxidant supplementation

From: SENIEUR status of the originating cell donor negates certain ‘anti-immunosenescence’ effects of ebselen and N-acetyl cysteine in human T cell clone cultures

Clone (Age of the donor)

Initial PD

Concentration

Average PD per week

Cumulative PD achieved at the end of lifespan in culture

400-23 (26 year old donor)

34.5

Control

0.7 ± 0.1

44.7 ± 0.3*

30 μM Ebselen

1.2 ± 0.2

56.2 ± 0.4*

385-7 (45 year old donor)

31.0

Control

1.0 ± 0.1

44.4 ± 0.3*

30 μM Ebselen

1.4 ± 0.4

50.8 ± 0.4*

399-37 (80 year old donor)

31.1

Control

1.2 ± 0.2

45.0 ± 0.4

  

30 μM Ebselen

1.2 ± 0.1

44.6 ± 0.3

Clone (Age of the donor)

Initial PD

Concentration

Average PD per week

Cumulative Pd achieved at the end of lifespan in culture

400-23 (26 year old donor)

34.5

Control

0.7 ± 0.1

44.7 ± 0.3*

7.5 mMNAC

1.2 ± 0.2

56.1 ± 0.3*

385-7 (45 year old donor)

31.0

Control

1.0 ± 0.1

44.4 ± 0.3*

7.5 mMNAC

1.4 ± 0.4

55.8 ± 0.4*

399-37 (80 year old donor)

31.1

Control

1.1 ± 0.2

44.2 ± 0.5

7.5 mMNAC

0.9 ± 0.2

42.3 ± 0.4

  1. Effect of Ebselen or NAC supplementation on the proliferative capacity and lifespan of CD4+ TCCs derived from healthy 26, 45 or 80 year old donors.
  2. Data of 26 and 45 year old donors are published data from [10]. *Significantly higher cumulative PDs in supplemented (+) clones compared to controls (-). n = 3 pooled TCCs for each age group.